Excipients for Injectables and Parenteral Formulations

Common challenges in parenteral formulation development include potential contamination throughout the process, introduced by manufacturing equipment, process chemicals and excipients, manufacturing personnel, or the environment (air). Implementing effective risk mitigation measures is vital to ensure final product quality and patient safety in these high-risk applications. Additional challenges include: Solubility and stability of the final formulation, sterility assurance, quality control, and navigating complex and evolving regulatory requirements. Read on in our technicle article “Parenteral Drugs: Ensuring Sterility and Minimizing Risks During Manufacturing”.

Endotoxins can trigger inflammatory reactions and adverse immune responses in patients. They may be introduced as contaminants in raw materials, process and excipients used to manufacture the parenteral formulation, or they can arise from bacterial contamination. Removing endotoxins from a final formulation is extremely challenging, making it critical to minimize their introduction and monitor levels throughout the process. When selecting excipients, it’s essential to account for the cumulative effect of endotoxins: While a single excipient may have endotoxin levels below regulatory limits, the combined contamination from endotoxins and bacteria multiple excipients and the process can result in a formulation that exceeds the regulatory limits for the respective application. It is therefore important to consciously select high-purity excipients and raw materials with specified low endotoxin and microbial levels for high-risk applications. Learn more in our dedicated webinar “Managing Endotoxins - Detect, Prevent, Remove”

Establishing stringent quality control as well as robust process monitoring and testing methods is key to ensure the safety and quality of your final product. Making an informed decision on the right sterilization technique is key and can be determined by various factors such as the API and formulation characteristics or material of the final packaging. Comprehensive risk assessment to identify potential issues in the manufacturing process and the implementation of risk mitigation measures throughout the process is required by regulatory authorities and can be supported by comprehensive information provided by suppliers. Using high-quality raw materials and excipients with low endotoxin and microbial levels can help meet the demands of parenteral application and ease risk assessment efforts. Read our technical article “Overcoming Excipient Risks and Challenges for Parenteral Formulations”